vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and SUNation Energy, Inc. (SUNE). Click either name above to swap in a different company.

SUNation Energy, Inc. is the larger business by last-quarter revenue ($27.2M vs $19.6M, roughly 1.4× STANDARD BIOTOOLS INC.). SUNation Energy, Inc. runs the higher net margin — 9.6% vs -177.4%, a 187.0% gap on every dollar of revenue. On growth, SUNation Energy, Inc. posted the faster year-over-year revenue change (77.0% vs -11.5%). Over the past eight quarters, SUNation Energy, Inc.'s revenue compounded faster (43.5% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Suncor Energy Inc. is a Canadian integrated energy company based in Calgary, Alberta. It specializes in production of synthetic crude from oil sands. In the 2020 Forbes Global 2000, Suncor Energy was ranked as the 48th-largest public company in the world.

LAB vs SUNE — Head-to-Head

Bigger by revenue
SUNE
SUNE
1.4× larger
SUNE
$27.2M
$19.6M
LAB
Growing faster (revenue YoY)
SUNE
SUNE
+88.5% gap
SUNE
77.0%
-11.5%
LAB
Higher net margin
SUNE
SUNE
187.0% more per $
SUNE
9.6%
-177.4%
LAB
Faster 2-yr revenue CAGR
SUNE
SUNE
Annualised
SUNE
43.5%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
SUNE
SUNE
Revenue
$19.6M
$27.2M
Net Profit
$-34.7M
$2.6M
Gross Margin
48.5%
40.7%
Operating Margin
-168.5%
10.7%
Net Margin
-177.4%
9.6%
Revenue YoY
-11.5%
77.0%
Net Profit YoY
-28.8%
138.2%
EPS (diluted)
$-0.09
$105.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
SUNE
SUNE
Q4 25
$27.2M
Q3 25
$19.6M
$19.0M
Q2 25
$21.8M
$13.1M
Q1 25
$40.8M
$12.6M
Q4 24
$15.4M
Q3 24
$22.1M
$14.7M
Q2 24
$22.5M
$13.5M
Q1 24
$45.5M
$13.2M
Net Profit
LAB
LAB
SUNE
SUNE
Q4 25
$2.6M
Q3 25
$-34.7M
$-393.0K
Q2 25
$-33.5M
$-9.6M
Q1 25
$-26.0M
$-3.5M
Q4 24
$-6.8M
Q3 24
$-26.9M
$-3.3M
Q2 24
$-45.7M
$-6.9M
Q1 24
$-32.2M
$1.2M
Gross Margin
LAB
LAB
SUNE
SUNE
Q4 25
40.7%
Q3 25
48.5%
38.0%
Q2 25
48.8%
37.0%
Q1 25
48.4%
35.1%
Q4 24
36.4%
Q3 24
54.9%
35.6%
Q2 24
46.1%
35.4%
Q1 24
53.1%
36.4%
Operating Margin
LAB
LAB
SUNE
SUNE
Q4 25
10.7%
Q3 25
-168.5%
-1.3%
Q2 25
-118.1%
-16.6%
Q1 25
-80.8%
-17.2%
Q4 24
-42.3%
Q3 24
-120.9%
-10.9%
Q2 24
-134.5%
-15.0%
Q1 24
-132.2%
-16.5%
Net Margin
LAB
LAB
SUNE
SUNE
Q4 25
9.6%
Q3 25
-177.4%
-2.1%
Q2 25
-153.7%
-73.5%
Q1 25
-63.8%
-27.7%
Q4 24
-44.4%
Q3 24
-122.0%
-22.4%
Q2 24
-203.3%
-51.2%
Q1 24
-70.6%
9.1%
EPS (diluted)
LAB
LAB
SUNE
SUNE
Q4 25
$105.59
Q3 25
$-0.09
$-0.12
Q2 25
$-0.09
$-3.14
Q1 25
$-0.07
$-106.71
Q4 24
$41676.94
Q3 24
$-0.07
$-2350.12
Q2 24
$-0.12
$-11022.91
Q1 24
$-0.27
$-38414.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
SUNE
SUNE
Cash + ST InvestmentsLiquidity on hand
$129.4M
$7.2M
Total DebtLower is stronger
$6.6M
Stockholders' EquityBook value
$399.7M
$24.3M
Total Assets
$539.6M
$48.2M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
SUNE
SUNE
Q4 25
$7.2M
Q3 25
$129.4M
$5.4M
Q2 25
$158.6M
$3.2M
Q1 25
$150.9M
$1.4M
Q4 24
$839.3K
Q3 24
$210.6M
$1.1M
Q2 24
$269.8M
$1.0M
Q1 24
$287.1M
$1.8M
Total Debt
LAB
LAB
SUNE
SUNE
Q4 25
$6.6M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
SUNE
SUNE
Q4 25
$24.3M
Q3 25
$399.7M
$21.7M
Q2 25
$424.5M
$22.1M
Q1 25
$454.6M
$14.8M
Q4 24
$8.5M
Q3 24
$489.3M
$13.1M
Q2 24
$510.3M
$-10.9M
Q1 24
$577.3M
$-11.2M
Total Assets
LAB
LAB
SUNE
SUNE
Q4 25
$48.2M
Q3 25
$539.6M
$49.6M
Q2 25
$557.0M
$44.1M
Q1 25
$579.6M
$44.4M
Q4 24
$45.7M
Q3 24
$681.5M
$51.0M
Q2 24
$708.7M
$52.9M
Q1 24
$777.7M
$54.7M
Debt / Equity
LAB
LAB
SUNE
SUNE
Q4 25
0.27×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
SUNE
SUNE
Operating Cash FlowLast quarter
$-22.2M
$2.1M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
0.81×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
SUNE
SUNE
Q4 25
$2.1M
Q3 25
$-22.2M
$2.4M
Q2 25
$-20.7M
$-130.2K
Q1 25
$-30.3M
$-3.4M
Q4 24
$-1.9M
Q3 24
$-27.9M
$-968.1K
Q2 24
$-39.0M
$-776.4K
Q1 24
$-62.5M
$-2.6M
Free Cash Flow
LAB
LAB
SUNE
SUNE
Q4 25
Q3 25
$-23.1M
$2.4M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
$-1.9M
Q3 24
$-30.1M
$-980.3K
Q2 24
$-41.0M
$-788.4K
Q1 24
$-63.3M
$-2.7M
FCF Margin
LAB
LAB
SUNE
SUNE
Q4 25
Q3 25
-118.1%
12.5%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
-12.4%
Q3 24
-136.4%
-6.7%
Q2 24
-182.2%
-5.8%
Q1 24
-138.9%
-20.1%
Capex Intensity
LAB
LAB
SUNE
SUNE
Q4 25
Q3 25
4.5%
0.0%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
0.0%
Q3 24
10.2%
0.1%
Q2 24
8.6%
0.1%
Q1 24
1.7%
0.0%
Cash Conversion
LAB
LAB
SUNE
SUNE
Q4 25
0.81×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-2.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

SUNE
SUNE

Transferred At Point In Time$15.1M55%
Hawaii Energy Connection$10.0M37%
Transferred Over Time$2.1M8%

Related Comparisons